Effect of nateglinide on the incidence of diabetes and cardiovascular events

R Holman, Steven Haffner, John McMurray, M Bethel, Bjoern Holzhauer, Tsushung Hua, Yuri Belenkov, Mitradev Boolell, John Buse, Brendan Buckley, Antonio Chacra, Fu-Tien Chiang, Bernard Charbonnel, Chun-Chung Chow, Melanie Davies, Prakash Deedwania, Peter Diem, Daniel Einhorn, Vivian Fonseca, Gregory FulcherZbigniew Gaciong, Sonia Gaztambide, Thomas Giles, Edward Horton, Hasan Ilkova, Trond Jenssen, Steven Kahn, Henry Krum, Markku Laakso, Lawrence Leiter, Naomi Levitt, Viacheslav Mareev, Felipe Martinez, Chantal Masson, Theodore Mazzone, Eduardo Meaney, Richard Nesto, Changyu Pan, Rudolf Prager, Sotirios Raptis, Guy Rutten, Herbert Sandstroem, Frank Schaper, Andre Scheen, Ole Schmitz, Isaac Sinay, Vladimir Soska, Steen Stender, Gyula Tamas, Gianni Tognoni, Jaakko Tuomilehto, Alberto Villamil, Juraj Vozar, Robert Califf

Research output: Contribution to journalArticleResearchpeer-review

381 Citations (Scopus)

Abstract

The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program.
Original languageEnglish
Pages (from-to)1463 - 1476
Number of pages14
JournalThe New England Journal of Medicine
Volume362
Issue number16
DOIs
Publication statusPublished - 2010

Cite this